Overview

Bioventix, the developer of sheep monoclonal antibodies used in diagnostic blood tests, released its unaudited interim report for the six months to 31 December 2025 on 30 March 2026. The key question is whether growing Alzheimer's-related royalties can offset softer sales elsewhere.

Background

Bioventix creates antibodies that other companies build into their diagnostic analysers, and it earns revenue from antibody sales and royalties. Its established products include vitamin D and troponin antibodies. A newer interest is neurology, where its antibodies are used in research assays for Tau, a protein linked to Alzheimer's disease.

Interim results

Turnover for the half-year was £6,158,816, down from £6,732,355 a year earlier, a fall of roughly 8.5%. Gross profit was £5,645,461 and operating profit £4,780,912, against £4,939,042. Profit before tax was £4,851,048 (previously £5,046,405), and profit after tax was £3,625,087. Basic earnings per share were 69.38 pence, compared with 72.27 pence. On a constant-currency basis the company reported revenue of £6.4m and profit before tax of £5.1m.

Cash at the bank stood at £5,303,901, net assets were £11,041,651, and net cash from operating activities was £4,367,108, up from £3,596,337. The company paid dividends of £4,179,888 during the period and declared an interim dividend of 70 pence per share, unchanged from the prior year, with an ex-dividend date of 9 April 2026 and payment on 24 April 2026. The board said it can use reserves to keep dividends at historic levels.

What drove the numbers

According to management, vitamin D and other core antibody sales were broadly in line with the previous year, though challenging conditions in China cost the company some limited revenue streams. Troponin sales were steady, but royalties have not yet risen following Siemens' US regulatory approval of a prognostic claim for its test.

The brighter spot was neurology. Tau and related royalties rose five-fold to £150,000 from £30,000, all of it from research-use-only Alzheimer's assays, because no in-vitro diagnostic assays for routine clinical use are yet approved. The company said several leading diagnostic and high-sensitivity research companies now include at least one of its antibodies in their Alzheimer's or total Tau assay designs. A water quality project and research with the University of Gothenburg on Tau tangle pathology are also continuing.

Why it matters

The business is small, highly profitable and cash generative, with an operating margin near 78% in the half-year. Its value depends on a handful of antibodies and on how many customers adopt them, which means regulatory milestones at partner companies can matter far more than its own cost base. A five-fold increase in Tau royalties is encouraging, but £150,000 is still tiny against turnover above £6m, so it is an option on the future rather than a current earnings driver.

Risks and limitations

Revenue and profit both fell, and dividends paid in the half-year (£4.18m) exceeded profit after tax (£3.63m), which is why the board refers to reserves. The results are unaudited. Currency swings and weakness in China are stated pressures. The company's comment that trading remained in line with expectations for the year to 30 June 2026 is a management statement, not a result.